The short answer
Retatrutide's literature is small but unusually strong: the discovery paper in Cell Metabolism, Phase 2 results in the New England Journal of Medicine and the Lancet, and a Phase 3 programme enrolling more than 5,800 participants reported through Lilly and ClinicalTrials.gov.
Key facts
- Discovery
- Coskun, Cell Metab 2022 (PMID 35985340)
- Phase 2 obesity
- Jastreboff, NEJM 2023 (PMID 37366315)
- Phase 2 T2D
- Rosenstock, Lancet 2023 (PMID 37385280)
- Phase 3 enrolment
- More than 5,800
- Evidence quality
- High (randomised, controlled)
- Chemical database entry
- None findable
An unusual profile for this library
Most compounds here have a large preclinical literature and no controlled human data. Retatrutide has the opposite: relatively few papers, but among them randomised controlled trials published in the New England Journal of Medicine and the Lancet, and a Phase 3 programme of more than 5,800 participants. On evidence quality it is not comparable to anything else in this catalogue.
The three foundational papers
Coskun and colleagues in Cell Metabolism, September 2022, for the discovery and pharmacology. Jastreboff and colleagues in the New England Journal of Medicine, 2023, for Phase 2 in obesity. Rosenstock and colleagues in the Lancet, 2023, for Phase 2 in type 2 diabetes. Almost everything else cites one of these.
Research material referenced
Retatrutide 10mg, third-party HPLC tested
Where the Phase 3 data lives
Topline results have been reported through Eli Lilly investor releases, with trials registered on ClinicalTrials.gov. Peer-reviewed publication follows database posting, so for the most recent readouts the investor release is currently the primary accessible source, which is a weaker form of reporting than a full paper.
The gap that is odd
For a compound with this much clinical evidence, retatrutide has no findable PubChem entry. Searches under the name, the development code and the reported CAS all return nothing. The clinical literature is stronger than almost anything else here while the chemical record is weaker, an inversion worth knowing about when checking a certificate of analysis.
How to search it
PubMed under retatrutide and LY3437943. ClinicalTrials.gov for the TRIUMPH registrations, searched directly rather than through secondary sources, because trial status changes. Lilly's investor releases for topline data ahead of publication. Each covers something the others do not.
What none of it establishes
That retatrutide is available or approved. It is investigational everywhere, and the strength of the trial evidence does not change its regulatory position. Research material supplied under this name is not the trial compound.
Frequently asked questions
How strong is retatrutide's evidence?
By the standards of this library, unusually strong. Randomised controlled trials in NEJM and the Lancet, and a Phase 3 programme of over 5,800 participants.
Where are the Phase 3 results published?
Topline data through Eli Lilly investor releases, with trials registered on ClinicalTrials.gov. Peer-reviewed publication follows.
Why is there no PubChem entry?
Not clear, and it is unusual for a compound at this stage. The clinical record is strong while the chemical record is not.
Continue researching
Peer-reviewed guides, comparators and matched reference materials.
Primary sources & clinical trials
Peer-reviewed research and registered trials from PubMed, ClinicalTrials.gov, PubChem, FDA and NIH. All links open in a new tab and point to the primary source, so every claim can be verified at origin.
- PubMedCoskun T et al. Cell Metab 2022 (PMID 35985340)pubmed.ncbi.nlm.nih.gov
- PubMedJastreboff AM et al. NEJM 2023 (PMID 37366315)pubmed.ncbi.nlm.nih.gov
- PubMedRosenstock J et al. Lancet 2023 (PMID 37385280)pubmed.ncbi.nlm.nih.gov
- TrialClinicalTrials.gov · TRIUMPH-1 (NCT05929066). Retatrutide Phase 3 obesity trialclinicaltrials.gov
- TrialClinicalTrials.gov · TRIUMPH-2 (NCT05929079). Retatrutide in type 2 diabetesclinicaltrials.gov
- TrialClinicalTrials.gov · TRIUMPH-3 (NCT05882045). Retatrutide + established CVDclinicaltrials.gov
- TrialClinicalTrials.gov · TRIUMPH-4 (NCT05931367). Retatrutide once weeklyclinicaltrials.gov
- TrialClinicalTrials.gov · TRIUMPH-5 (NCT06662383). Retatrutide vs tirzepatideclinicaltrials.gov
- TrialClinicalTrials.gov · TRIUMPH-6 (NCT06859268). Maintenance of weight reductionclinicaltrials.gov
- DrugBankDrugBank · Retatrutide (DB18435)go.drugbank.com
- GuidelineGoogle: Creating helpful, reliable, people-first contentdevelopers.google.com
Browse the wider literature
Live database searches, not fixed citations. Results change as new work is indexed.
Written and reviewed by
William Heath · Editor, UK Peptides research library
William Heath edits the UK Peptides research library. He is responsible for what is published here: every article is sourced to primary literature, every purity or identity statement traces to a signed third-party certificate for a specific lot, and corrections are made in place with the review date updated. No scientific or medical credentials are claimed on this site; the evidence is carried by the cited sources and the certificates, not by the byline.
More Retatrutide Research articles
- What Is the TRIUMPH Trial Programme?TRIUMPH is Eli Lilly's Phase 3 programme for retatrutide: 5,800+ participants. TRIUMPH-1 reported 28.3% mean weight reduction at 80 weeks in May 2026.
- How One Peptide Engages Three ReceptorsGIPR, GLP-1R and GCGR belong to one receptor family, which is what makes a single-molecule triple agonist possible at all.
- Retatrutide and AlcoholNo interaction study exists for retatrutide specifically. What the GLP-1 class literature reports about alcohol, and why the honest answer is narrow.
- Is There a Retatrutide Tablet or Pill?No oral retatrutide exists in any trial or any market. Why a 39-residue peptide cannot simply be pressed into a tablet, and what is being sold under that name.
- Fake Retatrutide and What a Certificate Can ProvePurity, identity and quantity are three separate questions and most certificates answer one. What HPLC and mass spectrometry establish, and what neither does.